Nonalcoholic fatty liver disease

1. calendar year is associated with nonalcoholic fatty liver disease in humans (OR 1.11, 95% CI 1.05–1.18).

   HumansAge-standardized analysis among health-checkup participants in Longhua District, Shenzhen2022 to 2024

   Multimorbidity patterns and temporal trends of chronic diseases among community-dwelling older adults: Repeated cross-sectional surveys from 2022 to 2024 · Experimental gerontology · 6 Oct 2026

1. Renin-angiotensin system inhibitors lower the risk of nonalcoholic fatty liver disease in humans (OR 0.73 [95% CI, 0.62-0.85]).

   Humans

   Antihypertensive Treatment and Risk of Metabolic Associated Fatty Liver Disease: A Drug-Target Mendelian Randomization · Hypertension (Dallas, Tex. : 1979) · 18 Sep 2026

Renin-angiotensin system inhibitors →

1. Systolic blood pressure lowers the risk of nonalcoholic fatty liver disease in humans (OR 0.92 [95% CI, 0.90-0.94]).

   Humansgenetically proxied 5-mm Hg reduction

   Antihypertensive Treatment and Risk of Metabolic Associated Fatty Liver Disease: A Drug-Target Mendelian Randomization · Hypertension (Dallas, Tex. : 1979) · 18 Sep 2026

Systolic blood pressure →

1. Nonalcoholic fatty liver disease raises the risk of type 2 diabetes in humans.

   Review

   Nonalcoholic Fatty Liver Disease as a Risk Marker for Incident Type 2 Diabetes Mellitus: A Systematic Review · Cureus · 31 Jul 2026

Type 2 diabetes →